Hormonal
Dietary omega-3 polyunsaturated fatty acids (specifically EPA) combined with aspirin or other NSAIDs generate novel anti-inflammatory lipid mediators (18R-HEPE, 5,12,18R-triHEPE, and 15-epi-LXA5) via transcellular processing involving COX-2 and leukocyte 5-lipoxygenase, which inhibit polymorphonuclear leukocyte (PMN) transendothelial migration and infiltration.
If you take omega-3 supplements (specifically EPA) and have inflammation (which upregulates COX-2), your body can convert these fats into potent anti-inflammatory signals, especially if you take aspirin or certain other NSAIDs. These signals actively stop immune cells from migrating to inflamed tissues. This suggests that the benefit of omega-3s is not just passive competition but active creation of anti-inflammatory mediators.
These new compounds proved to be potent inhibitors of human polymorphonuclear leukocyte transendothelial migration and infiltration in vivo (ATL analogue 5,12,18R-triHEPE).
Why this rating
The study uses rigorous biochemical identification (LC/MS/MS) and functional assays in human cells and murine models, though it is a mechanistic study rather than a large-scale clinical trial.
Source
Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing
Charles N. Serhan et al. · The Journal of Experimental Medicine · 2000
DOI 10.1084/jem.192.8.1197
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →